Mycobutin (Rifabutin)

Rifabutin exerts its antibacterial effect by binding to the β‑subunit of the bacterial DNA‑dependent RNA polymerase enzyme. This binding blocks the initiation of RNA synthesis, halting transcription of essential genes and ultimately leading to bacterial cell death. Its activity is focused on mycobacterial species, including those responsible for MAC and tuberculosis.

The specific dose of Mycobutin is determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and any concomitant medications. Healthcare professionals follow established clinical guidelines and adjust the regimen as needed; patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety data for rifabutin in pregnancy and lactation are limited, and the drug is generally classified as use‑only when the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and benefits with their healthcare provider before starting Mycobutin.

To request Mycobutin, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Rifabutin belongs to the rifamycin class and shares a similar mechanism with rifampin but has a longer half‑life and different drug‑interaction profile. It is often preferred when patients experience rifampin‑related adverse effects or when co‑administration with certain macrolides is needed, as it may cause fewer hepatotoxic events in some cases.

Mycobutin should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid storing it in areas with high humidity or extreme temperature fluctuations to maintain its stability.

Mycobutin is administered orally, typically as a tablet taken with or without food, according to the prescriber’s directions. The exact timing relative to meals may be specified to optimize absorption or reduce gastrointestinal discomfort, and patients should swallow the tablet whole with an adequate amount of water.

The most serious risks include severe neutropenia or leukopenia, which can predispose to infections; hepatotoxicity that may progress to hepatitis; and ocular inflammation such as uveitis, which can threaten vision if not identified promptly. Patients should be monitored regularly for blood counts, liver function, and eye symptoms during therapy.

Mycobutin should be avoided in individuals with known hypersensitivity to rifabutin or any rifamycin‑class drug. Caution is also advised for patients with severe hepatic impairment, uncontrolled neutropenia, or those receiving contraindicated interacting medications without appropriate monitoring or dose adjustment.